CLINICAL_TRIALS
trial_result
· 2019-10-30
Clinical Trial Update: FET-PET for Evaluation of Response of Recurrent GBM to Avastin [Phase 2]
Summary
Phase 2 trial evaluating FET-PET to assess response of recurrent glioblastoma to Avastin has completed with results posted in 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Marcelo F. Di Carli, MD, FACC | Conditions: Glioblastoma Multiforme, GBM | Phase 2 | Status: COMPLETED | Results posted: 2019-10-30